Author:
,Holmes David R.,Dehmer Gregory J.,Kaul Sanjay,Leifer Dana,O'Gara Patrick T.,Stein C. Michael
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference74 articles.
1. FDA Drug Safety Communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm203888.htm. Accessed April 28 2010.
2. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
3. Relation of Cytochrome P450 2C19 Loss-of-Function Polymorphism to Occurrence of Drug-Eluting Coronary Stent Thrombosis
4. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
5. Stockbridge N. FDA Letter of Approval: May 5 2009 NDA 20-839/S-040. U.S. Food and Drug Administration. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/020839s040ltr.pdf. Accessed April 29 2010.
Cited by
170 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献